Clinical Trials Browser

Approved for marketing × ivosidenib × Clear all

NCT03245424 2018-07-24

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Approved for marketing

Other hematologic neoplasm

Leukemia, Myeloid, Acute